Praveen Akuthota, MD
Critical Care Medicine · San Diego, CANPI 1396704698
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $140,374 of the $168,818 with a category attached, or 83.2%. 8 manufacturers reported payments, led by Sanofi at 28.1% of the total. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $1156.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$47K
- Astrazeneca UK Limited$42K
- AstraZeneca$36K
- GSK$26K
- Astrazeneca AB$14K
- Amgen$3K
- plus $493 from 2 others
Across 44 payments — averaging $15,271 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$192K
- AstraZeneca$118K
- Astrazeneca UK Limited$113K
- Sanofi-aventis U.S. LLC$104K
- GSK$61K
- Regeneron$49K
- plus $35K from 1 others
What the payments were for
- Consulting fees$140,37483%
- Speaking & faculty fees$4,6503%
- Travel & lodging$20,05012%
- Food & beverage$3,7232%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 15 | $47,476 |
| Astrazeneca UK Limited | 64 | $41,916 |
| AstraZeneca | 42 | $35,653 |
| GSK | 10 | $26,189 |
| Astrazeneca AB | 10 | $13,991 |
| Amgen | 1 | $3,100 |
| Sanofi US Services Inc. | 3 | $340 |
| ZOLL Respicardia, Inc. | 1 | $152 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$30,849
- NUCALA$9,913
- TRELEGY ELLIPTA$2,925
- remede System$152
How this compares
$168,818 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 64 | $609,798 |
| TezspireTezepelumab-Ekko | 80 | $342,550 |
| Fasenra PenBenralizumab | 55 | $285,060 |
| Dupixent PenDupilumab | 46 | $163,225 |
| Dupixent SyringeDupilumab | 36 | $134,763 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $27,127 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,087 |
| DuleraMometasone/Formoterol | 25 | $8,423 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,806 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,649 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,311 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,741 |
| Ventolin HfaAlbuterol Sulfate | 11 | $989 |
| Montelukast Sodium | 45 | $620 |
| Prednisone | 64 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $26,189 | $643,73296 claims |
| AstraZenecaTezspire, Symbicort | $35,653 | $348,19999 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.
Other critical care medicine in San Diego
- Xuanha WhiteSan Diego$343K
- Wael El MaraachliSan Diego$126K
- Aarya KafiSan Diego$34K
- Anushirvan MinokadehSan Diego$33K
- Mona AlotaibiSan Diego$13K
- Jeffrey BarrySan Diego$11K
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.